推荐产品
形狀
powder
品質等級
起源
Abbott
儲存溫度
2-8°C
SMILES 字串
Cl[H].CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2
InChI
1S/C21H27NO3.ClH/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17;/h3-11,18,22-23H,2,12-16H2,1H3;1H
InChI 密鑰
XWIHRGFIPXWGEF-UHFFFAOYSA-N
基因資訊
human ... ABCB1(5243) , ADRB1(153) , ADRB2(154) , ADRB3(155) , CYP1A2(1544) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
正在寻找类似产品? 访问 产品对比指南
一般說明
Propafenone hydrochloride is a calcium antagonist. It functions as a Na+ and K+ channel blocker. It might be used to treat patients with systemic hypertension. Propafenone hydrochloride is associated with bradycardia and bronchospasms. It is metabolized in the liver. Propafenone hydrochloride is used to treat ventricular arrhythmias.
應用
Propafenone hydrochloride has been used in the isolation of cardiomyocytes.
生化/生理作用
Blocks hKv1.5 and ATP-sensitive K+ channels; class 1C antiarrhythmic agent that is also an antagonist at β adrenergic receptors.
特點和優勢
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
Propafenone hepatotoxicity: report of a new case and review of the literature
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association, 19(5), 235-235 (2013)
Pharmacologic management of arrhythmias
Texas Heart Institute Journal, 38(4), 344-344 (2011)
Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study
Chest, 126(2), 476-486 (2004)
Cardiovascular drugs and therapy, 26(2), 167-179 (2012-03-16)
Rate and rhythm control are two well established treatment objectives for atrial fibrillation (AF) patients. While symptom reduction is a primary treatment goal, therapeutic practice related to cardioversion varies by region and patient, with several precautions associated with the use
The Journal of pharmacology and experimental therapeutics, 340(1), 161-168 (2011-10-19)
Ranolazine has been shown to produce atrial-selective depression of sodium channel-dependent parameters and suppress atrial fibrillation (AF) in a variety of experimental models. The present study contrasts the effects of ranolazine and those of a clinically used anti-AF class IC
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门